<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279019</url>
  </required_header>
  <id_info>
    <org_study_id>AC2103473</org_study_id>
    <nct_id>NCT00279019</nct_id>
  </id_info>
  <brief_title>Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Inhaled Doses of GSK233705 and Tiotropium Bromide (18Âµg) Via DPI in COPD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
      developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
      duration of action of GSK233705 when administered via inhalation in animal models supports
      the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary
      disease.

      GSK233705 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being
      developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long
      duration of action of GSK233705 when administered via inhalation in animal models supports
      the potential for use as a once-daily bronchodilator for chronic obstructive pulmonary
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2005</start_date>
  <completion_date type="Actual">June 13, 2006</completion_date>
  <primary_completion_date type="Actual">June 13, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, blood pressure, heart rate, 12-lead electrocardiogram (ECG), Holter and Lead II ECG monitoring, ECG, lung function and clinical laboratory safety tests.</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentrations of GSK233705 and derived pharmacokinetic parameters. Serial IOS and FEV1 measurements over 27 hours post-dose Serial sGaw, Raw measurements over 24 hours post-dose.</measure>
    <time_frame>Pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours Post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment sequence 16</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK233705</intervention_name>
    <description>GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.</description>
    <arm_group_label>Subjects receiving treatment sequence 6</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 16</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 14</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 8</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 10</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 12</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 9</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 11</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 13</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 15</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.</description>
    <arm_group_label>Subjects receiving treatment sequence 6</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 16</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 14</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 8</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 10</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 12</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 9</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 11</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 13</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 15</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose</description>
    <arm_group_label>Subjects receiving treatment sequence 6</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 16</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 14</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 8</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 10</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 4</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 12</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 9</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 3</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 2</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 5</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 11</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 13</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 15</arm_group_label>
    <arm_group_label>Subjects receiving treatment sequence 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Of non-childbearing potential.

          -  Diagnosed with COPD, as defined by the GOLD guidelines.

          -  Smoker or an ex-smoker with a smoking history of at least 10 pack years.

          -  FEV1/FVC &lt; 0.7 post-bronchodilator (salbutamol).

          -  FEV1 &lt;= 80% of predicted normal for height, age and gender after inhalation of
             salbutamol.

          -  Response to ipratropium bromide 9.

          -  Subject's weight is 60kg.

        Exclusion criteria:

          -  Past or present disease, which as judged by the Investigator and the Medical Monitor,
             may affect the outcome of this study.

          -  FEV1 &lt;=50% of predicted after inhalation of salbutamol.

          -  Tested positive for hepatitis C antibody, hepatitis B surface antigen or HIV.

          -  Has claustrophobia that may be aggravated by entering the plethysmography cabinet.

          -  Has prostate hypertrophy or narrow angle glaucoma.

          -  Diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis,
             allergic rhinitis, or asthma.

          -  Poorly controlled COPD.

          -  Participated in a Pulmonary Rehabilitation Program within 4 weeks prior to screening
             visit or will enter a program during the study.

          -  Had a respiratory tract infection in the 4 weeks prior to the screening visit and
             throughout the duration of the study.

          -  History of congestive heart failure, coronary insufficiency or cardiac arrhythmia.

          -  A mean QTc(B) value at screening &gt;440msec, the QTc(B) of all 3 screening ECGs are not
             within 10% of the mean, a PR interval outside the range 120-210msec or an ECG that is
             not suitable for QT measurements.

          -  A history of elevated supine blood pressure or a mean blood pressure equal to or
             higher than 160/95 mmHg.

          -  A mean heart rate outside the range 40-90 bpm.

          -  QTc prolongation &gt;470msec or risk factors for torsades de pointes (heart failure NYHA
             II-IV, hypokalaemia, familial long QT syndrome).

          -  Receiving co-medication with drugs which prolong the QTc interval.

          -  Requires treatment with inhaled cromolyn sodium or nedocromil, oral beta-2-agonists,
             nebulised beta-2-agonists, nebulised anticholinergics or leukotriene modifiers.

          -  Unable to abstain from xanthines (other than caffeine.

          -  Unable to abstain from short-acting inhaled bronchodilators.

          -  Unable to abstain from long-acting inhaled bronchodilators.

          -  Changed dose of inhaled or oral corticosteroids within the last 6 weeks.

          -  Taking more than 10mg/day of prednisolone (or equivalent).

          -  Receiving treatment with long term or short-term oxygen therapy or requires nocturnal
             positive pressure for sleep apnea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grosshansdorf</city>
        <state>Schleswig-Holstein</state>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/AC2103473?search=study&amp;study_ids=2103473#rs</url>
    <description>Results for study AC2103473 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2006</study_first_submitted>
  <study_first_submitted_qc>January 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2006</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK233705</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>AC2103473</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

